Healthpeak Properties, Inc.

DOC · NYSE · USD

Can Healthpeak turn a recovering lab leasing pipeline into rising earnings fast enough to offset the rent it loses from expiring leases?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Life science leasing recovery

    Lab demand is recovering and Healthpeak is winning more than its share of the leasing, so occupancy should rebuild rather than keep falling.

  • Outpatient rent growth

    Outpatient medical has produced steady rent growth for years, and the largest institutional investors now want to own those buildings alongside Healthpeak.

  • Senior housing separation

    The senior housing IPO turned a portfolio the market ignored into a separately valued company, and Healthpeak kept most of the ownership.

  • Capital recycling

    Asset sales at low cap rates fund development at higher yields, so the company can grow without issuing equity or stretching its balance sheet.

Bear case

  • Lagging lab earnings

    Lab earnings are still falling because leases lost last year only reach the income statement now, so profit per share is lower than a year ago.

  • Negative free cash flow

    Free cash flow has turned negative as development and redevelopment spending outruns the cash the properties produce.

  • Biotech tenant funding

    Lab tenants are mostly small biotechs that depend on raising capital, and the portfolio is concentrated in a handful of submarkets.

  • Joint venture reliance

    Growth now relies on joint venture partners and asset sales rather than on rent increases from the existing portfolio.

Bull and bear points

Growth & Execution

In short: Lab leasing is recovering and outpatient demand is steady, while earnings still lag behind signed leases.

Bull · 2

  • Lab occupancy guidance flipped from decline to growth

    Management once told investors lab occupancy would keep falling toward the high 70s; it now expects total lab occupancy to rise this year, which supports the case that segment earnings bottom this year.

    Tone shiftQ3 FY2025 → Q2 FY2026

  • Outpatient leasing pipeline points to faster growth in 2027

    Renewals keep coming at positive spreads with minimal tenant improvement spending, so the largest segment can grow cash flow without much added capital.

    Q2 FY2026 call
Bear · 2

  • Lost lab leases still cut 2026 earnings

    Management said the occupancy lost in the lab portfolio reduces earnings this year by about 12 cents a share, so profit per share falls even while new leasing improves.

    Q4 FY2025 call

  • Outpatient revenue fell as buildings were sold

    The largest segment is shrinking on the income statement because properties are moved into joint ventures, so reported growth depends on redeploying that cash at higher returns.

    Filed financials

Profitability & Financial Strength

In short: Leverage is low and asset sales price well, but free cash flow is negative on development spending.

Bull · 2

  • Management keeps leverage below its target

    Management said it can run leverage below its long-term target rather than up to it, which leaves room to absorb higher refinancing costs in a year with large maturities.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Joint venture recaps raise equity at low cap rates

    The Brookfield recap keeps Healthpeak as operator and majority owner while returning cash it can put into pre-leased outpatient developments yielding more than the assets sold.

    Q2 FY2026 call
Bear · 2

  • Free cash flow turned negative as capital spending doubled

    Free cash flow was negative $499 million over the past year, so growth is being funded by asset sales and debt rather than by cash the properties generate.

    Filed financials

  • Gross margin fell 6.2 points to 54.0%

    Consolidating the senior housing business adds revenue that carries operating costs, so reported margins are lower even though that segment's cash flow is growing.

    Filed financials

Market Position

In short: Healthpeak leads its core outpatient and lab markets, but lab rents are soft and tenants are small.

Bull · 2

  • Blackstone and Brookfield chose Healthpeak as operating partner

    Two large institutional investors with no prior outpatient exposure bought into the platform, which gives Healthpeak a repeatable source of equity to fund growth.

    Q2 FY2026 call

  • South San Francisco footprint covers a third of the submarket

    The Gateway purchase added 1.4 million square feet next to existing holdings, letting Healthpeak offer tenants space at several sizes and price points in the strongest Bay Area lab market.

    Q4 FY2025 call
Bear · 2

  • Lab rents are drifting lower and free rent is rising

    With vacancy still high in Boston and other markets, renewals may reset at lower face rents, which slows how much earnings a given occupancy gain produces.

    Q4 FY2025 call

  • Lab tenants are small biotechs dependent on capital raising

    Management watches tenants with less than a year of cash, so a closed capital market would turn watch-list names into vacancy instead of rent.

    Q3 FY2025 call